These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
784 related articles for article (PubMed ID: 22773810)
1. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810 [TBL] [Abstract][Full Text] [Related]
2. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798 [TBL] [Abstract][Full Text] [Related]
3. Genetic predictors of MEK dependence in non-small cell lung cancer. Pratilas CA; Hanrahan AJ; Halilovic E; Persaud Y; Soh J; Chitale D; Shigematsu H; Yamamoto H; Sawai A; Janakiraman M; Taylor BS; Pao W; Toyooka S; Ladanyi M; Gazdar A; Rosen N; Solit DB Cancer Res; 2008 Nov; 68(22):9375-83. PubMed ID: 19010912 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224 [TBL] [Abstract][Full Text] [Related]
5. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644 [TBL] [Abstract][Full Text] [Related]
6. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Huang MH; Lee JH; Chang YJ; Tsai HH; Lin YL; Lin AM; Yang JC Mol Oncol; 2013 Feb; 7(1):112-20. PubMed ID: 23102728 [TBL] [Abstract][Full Text] [Related]
7. EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines. Kim SM; Kim H; Jang KW; Kim MH; Sohn J; Yun MR; Kang HN; Kang CW; Kim HR; Lim SM; Moon YW; Kim JH; Paik S; Cho BC Mol Cancer Ther; 2016 Jul; 15(7):1627-36. PubMed ID: 27196768 [TBL] [Abstract][Full Text] [Related]
8. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072 [TBL] [Abstract][Full Text] [Related]
9. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Yu HA; Arcila ME; Rekhtman N; Sima CS; Zakowski MF; Pao W; Kris MG; Miller VA; Ladanyi M; Riely GJ Clin Cancer Res; 2013 Apr; 19(8):2240-7. PubMed ID: 23470965 [TBL] [Abstract][Full Text] [Related]
10. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556 [TBL] [Abstract][Full Text] [Related]
11. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471 [TBL] [Abstract][Full Text] [Related]
12. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. Gandhi J; Zhang J; Xie Y; Soh J; Shigematsu H; Zhang W; Yamamoto H; Peyton M; Girard L; Lockwood WW; Lam WL; Varella-Garcia M; Minna JD; Gazdar AF PLoS One; 2009; 4(2):e4576. PubMed ID: 19238210 [TBL] [Abstract][Full Text] [Related]
13. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212 [TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Kotoula V; Sozopoulos E; Litsiou H; Fanourakis G; Koletsa T; Voutsinas G; Tseleni-Balafouta S; Mitsiades CS; Wellmann A; Mitsiades N Endocr Relat Cancer; 2009 Jun; 16(2):565-72. PubMed ID: 19190079 [TBL] [Abstract][Full Text] [Related]
15. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer. Owen DH; Konda B; Sipos J; Liu T; Webb A; Ringel MD; Timmers CD; Shah MH J Natl Compr Canc Netw; 2019 May; 17(5):409-413. PubMed ID: 31085763 [TBL] [Abstract][Full Text] [Related]
17. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Gazdar AF Oncogene; 2009 Aug; 28 Suppl 1(Suppl 1):S24-31. PubMed ID: 19680293 [TBL] [Abstract][Full Text] [Related]
18. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267 [TBL] [Abstract][Full Text] [Related]
19. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323 [TBL] [Abstract][Full Text] [Related]
20. Drug Resistance to EGFR Inhibitors in Lung Cancer. Tetsu O; Hangauer MJ; Phuchareon J; Eisele DW; McCormick F Chemotherapy; 2016; 61(5):223-35. PubMed ID: 26910730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]